TMC
CLDX icon

Trellus Management Company’s Celldex Therapeutics CLDX Stock Holding History

Trellus Management Company’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-747
Closed -$183K – 117
2014
Q2 		$183K Buy
+747
New +$169K 0.15% 106

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Trellus Management Company's CLDX Position: Q3 2014 in Review

Trellus Management Company sold out of Celldex Therapeutics (CLDX) in Q3 2014, closing a stake of 747 shares — an estimated $183K sold.

Trellus Management Company first reported a position in CLDX in Q2 2014 and held it in 1 quarter. The position peaked at $183K in Q2 2014. 148 funds tracked by Wall St. Rank hold CLDX as of Q3 2014.

  • Trellus Management Company reported no remaining Celldex Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Trellus Management Company sold 747 Celldex Therapeutics shares in Q3 2014, an estimated $183K.
  • Trellus Management Company first reported a position in Celldex Therapeutics in Q2 2014 and held it in 1 quarter.
  • Trellus Management Company's Celldex Therapeutics position peaked at $183K in Q2 2014.
  • 148 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2014.

Based on Trellus Management Company's 13F filing for Q3 2014, filed 13 Nov 2014.